EUCTR2012-005431-86-NL进行中（未招募）不适用
Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide. - 18F-FDHT PET/CT as an early Treatment Response marker
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Age 50 or older.
- •2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
- •3. Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone analogue or bilateral orchidectomy.
- •4. Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease.
- •5. Metastatic disease documented by bone lesions on bone scan or by measurable soft tissue disease by CT
- •6. No prior cytotoxic chemotherapy for prostate cancer.
- •7. Asymptomatic or mildly symptomatic from prostate cancer
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
- •2. Known or suspected brain metastasis or active leptomeningeal disease.
- •3. History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer.
研究者
相似试验
已完成
不适用
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.lung cancerNL-OMON48669Antoni van Leeuwenhoek Ziekenhuis50
Unknown
不适用
Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.Castration-resistant prostate cancerNL-OMON20629niversity Medical Center Groningen60
Unknown
不适用
Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer PatientsEndometrial CancerNCT05056259Assiut University42
已完成
3 期
Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.10027476Prostate cancerNL-OMON41464niversitair Medisch Centrum Groningen60
进行中（未招募）
1 期
Study to see if new research scans can show how treatment affects the blood supply to kidney cancersPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002833-20-GBOxford University Hospitals NHS Trust10